GCI Health
Daclizumab shows potential for new immunoregulatory approach to treating MS
Published in Disease Risk Factor Week, March 7th, 2010
Biogen Idec (NASDAQ: BIIB) and Facet Biotech Corporation (NASDAQ: FACT) announced the publication of Phase 2 data showing that the addition of daclizumab to interferon beta (IFN(beta)) led to a significant reduction in the number of new or enlarged multiple sclerosis (MS) lesions when compared to IFN(beta) alone in patients with active relapsing forms of MS. The trial, called CHOICE, also showed that daclizumab led to an increase in a subset of the natural killer (NK) cells that help regulate the immune system. These data were published in Online First, the online edition of The Lancet Neurology, and will be published in the April issue of the Lancet Neurology.
Study...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Disease Risk Factor Week
More Articles from Disease Risk Factor Week
- Adolescence
Reports from Virginia Commonwealth University advance knowledge in adolescence - Alcohol Drinking
Studies from I. Wakabayashi et al add new findings in the area of alcohol drinking - Alzheimer Disease
Research findings from Chongqing Medical University update understanding of Alzheimer disease - Alzheimer Disease
Researchers from Indiana University, Medical Department describe findings in Alzheimer disease - Alzheimer Disease
Study results from Capital Medical University in the area of Alzheimer disease published - Alzheimer Disease Genetics
Research in the area of Alzheimer disease genetics reported from Chang Gung University - More from this issue of Disease Risk Factor Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
